Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 144

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides

Floquet, Célia, Deforges, Jules, Rousset, Jean-Pierre, Bidou, Laure·2011·Nucleic Acids Research
DOI 10.1093/nar/gkq1277
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/nar/gkq1277

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 56

  1. Burke, 1985, Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin, Nucleic Acids Res., 13, 6265, 10.1093/nar/13.17.6265 · DOI · Paper page
  2. Barton-Davis, 1999, Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice, J. Clin. Invest., 104, 375, 10.1172/JCI7866 · DOI · Paper page
  3. Bedwell, 1997, Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line, Nat. Med., 3, 1280, 10.1038/nm1197-1280 · DOI · Paper page
  4. Linde, 2008, Introducing sense into nonsense in treatments of human genetic diseases, Trends Genet., 24, 552, 10.1016/j.tig.2008.08.010 · DOI · Paper page
  5. Zingman, 2007, Aminoglycoside-induced translational read-through in disease: overcoming nonsense mutations by pharmacogenetic therapy, Clin. Pharmacol. Ther., 81, 99, 10.1038/sj.clpt.6100012 · doi:10.1038/sj.clpt.6100012
  6. Wilschanski, 2003, Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations, N. Engl. J. Med., 349, 1433, 10.1056/NEJMoa022170 · DOI · Paper page
  7. Clancy, 2001, Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis, Am. J. Respir. Crit. Care Med., 163, 1683, 10.1164/ajrccm.163.7.2004001 · DOI · Paper page
  8. Wagner, 2001, Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations, Ann. Neurol., 49, 706, 10.1002/ana.1023 · DOI · Paper page
  9. Politano, 2003, Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results, Acta Myol., 22, 15
  10. Malik, 2010, Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy, Ann. Neurol., 67, 771, 10.1002/ana.22024 · DOI · Paper page
  11. Sermet-Gaudelus, 2007, In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study, BMC Med., 5, 5, 10.1186/1741-7015-5-5 · DOI · Paper page
  12. Giaccia, 1998, The complexity of p53 modulation: emerging patterns from divergent signals, Genes Dev., 12, 2973, 10.1101/gad.12.19.2973 · DOI · Paper page
  13. Wagner, 1994, Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1, Genes Dev., 8, 2817, 10.1101/gad.8.23.2817 · DOI · Paper page
  14. Lowe, 1994, p53 status and the efficacy of cancer therapy in vivo, Science, 266, 807, 10.1126/science.7973635 · DOI · Paper page
  15. El-Deiry, 2003, The role of p53 in chemosensitivity and radiosensitivity, Oncogene, 22, 7486, 10.1038/sj.onc.1206949 · DOI · Paper page
  16. Lowe, 1993, p53-dependent apoptosis modulates the cytotoxicity of anticancer agents, Cell, 74, 957, 10.1016/0092-8674(93)90719-7 · DOI · Paper page
  17. Takahashi, 1992, Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions, Cancer Res., 52, 2340
  18. Casey, 1991, Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene, Oncogene, 6, 1791
  19. Chen, 1996, p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells, Genes Dev., 10, 2438, 10.1101/gad.10.19.2438 · DOI · Paper page
  20. Roth, 2006, Adenovirus p53 gene therapy, Expert. Opin. Biol. Ther., 6, 55, 10.1517/14712598.6.1.55 · DOI
  21. Peng, 2005, Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers, Hum. Gene Ther., 16, 1016, 10.1089/hum.2005.16.1016 · DOI · Paper page
  22. Selivanova, 2010, Therapeutic targeting of p53 by small molecules, Semin. Cancer Biol., 20, 46, 10.1016/j.semcancer.2010.02.006 · DOI
  23. Wang, 2010, Targeting p53 for novel anticancer therapy, Transl. Oncol., 3, 1, 10.1593/tlo.09250 · DOI
  24. Tang, 2007, CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice, J. Clin. Invest., 117, 3753, 10.1172/JCI32481 · DOI · Paper page
  25. Magrini, 2008, PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells, J. Cell Biochem., 104, 2363, 10.1002/jcb.21794 · DOI
  26. Zache, 2008, PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53, Cell Oncol., 30, 411
  27. Bidou, 2004, Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment, Gene Ther., 11, 619, 10.1038/sj.gt.3302211 · DOI
  28. Wang, 2000, Establishment and characterization of a new cell line derived from a human primary breast carcinoma, Cancer Genet. Cytogenet., 120, 58, 10.1016/S0165-4608(99)00253-8 · doi:10.1016/s0165-4608(99)00253-8
  29. Bidou, 2000, Nonsense-mediated decay mutants do not affect programmed -1 frameshifting, RNA, 6, 952, 10.1017/S1355838200000443 · DOI
  30. Howard, 2004, Readthrough of dystrophin stop codon mutations induced by aminoglycosides, Ann. Neurol., 55, 422, 10.1002/ana.20052 · DOI
  31. Allamand, 2008, Drug-induced readthrough of premature stop codons leads to the stabilization of laminin alpha2 chain mRNA in CMD myotubes, J. Gene Med., 10, 217, 10.1002/jgm.1140 · DOI
  32. Salvatori, 2009, Production of beta-globin and adult hemoglobin following G418 treatment of erythroid precursor cells from homozygous beta(0)39 thalassemia patients, Am. J. Hematol., 84, 720, 10.1002/ajh.21539 · DOI
  33. Stagliano, 2003, Real-time polymerase chain reaction quantitation of relative expression of genes modulated by p53 using SYBR Green I, Methods Mol. Biol., 234, 73
  34. Rowe, 2009, Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development, BioDrugs, 23, 165, 10.2165/00063030-200923030-00003 · DOI
  35. Keeling, 2002, Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system, J. Mol. Med., 80, 367, 10.1007/s00109-001-0317-z · DOI
  36. Zilberberg, 2010, Restoration of APC gene function in colorectal cancer cells by aminoglycoside- and macrolide-induced read-through of premature termination codons, Gut, 59, 496, 10.1136/gut.2008.169805 · DOI
  37. Howard, 2000, Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy, Ann. Neurol., 48, 164, 10.1002/1531-8249(200008)48:2<164::AID-ANA5>3.0.CO;2-B · doi:10.1002/1531-8249(200008)48:2<164::aid-ana5>3.0.co;2-b
  38. Manuvakhova, 2000, Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system, RNA, 6, 1044, 10.1017/S1355838200000716 · DOI · Paper page
  39. Bellais, 2010, In vitro readthrough of termination codons by gentamycin in the Stuve-Wiedemann Syndrome, Eur. J. Hum. Genet., 18, 130, 10.1038/ejhg.2009.122 · doi:10.1038/ejhg.2009.122
  40. Nicholson, 2010, Nonsense-mediated mRNA decay in human cells: mechanistic insights, functions beyond quality control and the double-life of NMD factors, Cell Mol. Life Sci., 67, 677, 10.1007/s00018-009-0177-1 · DOI · Paper page
  41. Kuzmiak, 2006, Applying nonsense-mediated mRNA decay research to the clinic: progress and challenges, Trends Mol. Med., 12, 306, 10.1016/j.molmed.2006.05.005 · DOI · Paper page
  42. Muhlemann, 2008, Recognition of nonsense mRNA: towards a unified model, Biochem. Soc. Trans., 36, 497, 10.1042/BST0360497 · DOI
  43. Losson, 1979, Interference of nonsense mutations with eukaryotic messenger RNA stability, Proc. Natl Acad. Sci. USA, 76, 5134, 10.1073/pnas.76.10.5134 · DOI · Paper page
  44. Keeling, 2004, Leaky termination at premature stop codons antagonizes nonsense-mediated mRNA decay in S. cerevisiae, RNA, 10, 691, 10.1261/rna.5147804 · DOI · Paper page
  45. Moriarty, 1998, Selenium deficiency reduces the abundance of mRNA for Se-dependent glutathione peroxidase 1 by a UGA-dependent mechanism likely to be nonsense codon-mediated decay of cytoplasmic mRNA, Mol. Cell. Biol., 18, 2932, 10.1128/MCB.18.5.2932 · DOI · Paper page
  46. Weiss, 1998, Cis-acting elements are required for selenium regulation of glutathione peroxidase-1 mRNA levels, RNA, 4, 816, 10.1017/S1355838298971990 · DOI
  47. Mingeot-Leclercq, 1999, Aminoglycosides: nephrotoxicity, Antimicrob. Agents Chemother., 43, 1003, 10.1128/AAC.43.5.1003 · DOI · Paper page
  48. Guthrie, 2008, Aminoglycoside induced ototoxicity, Toxicology, 249, 91, 10.1016/j.tox.2008.04.015 · DOI · Paper page
  49. Yang, 2007, A mouse model for nonsense mutation bypass therapy shows a dramatic multiday response to geneticin, Proc. Natl Acad. Sci. USA, 104, 15394, 10.1073/pnas.0610878104 · DOI
  50. Takamoto, 2005, Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in SGLT1 activity induced by gentamicin C, Biochim. Biophys. Acta, 1722, 247, 10.1016/j.bbagen.2004.12.006 · DOI
  51. Du, 2009, Poly-L-aspartic acid enhances and prolongs gentamicin-mediated suppression of the CFTR-G542X mutation in a cystic fibrosis mouse model, J. Biol. Chem., 284, 6885, 10.1074/jbc.M806728200 · DOI
  52. Nudelman, 2010, Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations, Bioorg. Med. Chem., 18, 3735, 10.1016/j.bmc.2010.03.060 · DOI
  53. Welch, 2007, PTC124 targets genetic disorders caused by nonsense mutations, Nature, 447, 87, 10.1038/nature05756 · DOI · Paper page
  54. Du, 2008, PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model, Proc. Natl Acad. Sci. USA, 105, 2064, 10.1073/pnas.0711795105 · DOI · Paper page
  55. Hamed, 2006, Drug evaluation: PTC-124–a potential treatment of cystic fibrosis and Duchenne muscular dystrophy, IDrugs, 9, 783
  56. Sermet-Gaudelus, 2010, Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis, Am. J. Respir. Crit. Care Med., 182, 1262, 10.1164/rccm.201001-0137OC · DOI

Cited by

See all 144

Metadata

Authors
Floquet, C., Deforges, J., Rousset, J.-P., & Bidou, L.
Venue
Nucleic Acids Research
Publisher
Oxford University Press (OUP)
Published
2010-12-10
Volume
39
Issue
8
Pages
3350-3362
ISSN
  • 1362-4962
  • 0305-1048
DOI
10.1093/nar/gkq1277
Cited by
144
References
2
Language
en
Licence
creativecommons.org/licenses/by-nc/2.5 (vor, 2159 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. https://app.cochat.ai/papers/10.1093/nar/gkq1277
The paper
Floquet, C., Deforges, J., Rousset, J.-P., & Bidou, L. (2011). Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. Nucleic Acids Research. https://doi.org/10.1093/nar/gkq1277

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.